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SUMMARY
A new method of determining class II HLA antigens by genotyping with HLA
DNA probes is described. This method compares favourably to the traditional
serological methods.
INTRODUCTION
HLA cell-surface antigens are involved in various functions of the immune
system, such as co-operation between lymphocyte subsets, antigen presentation
and allograft rejection.' Some HLA antigens have been shown to be associated
with susceptibility to certain diseases.2 Bone marrow transplantation usually
requires an identical HLA match between donor and patient for class I (HLA-A,
-B, -C) and class II (HLA-DR, -DQ, -DP) antigens.3 Although a complete
match is not an absolute requirement in kidney transplantation, there is a
significant improvement of graft survival between the best and worst matches for
HLA -A, -B and -DR antigens.4,5.6
HLA typing is traditionally performed according to immunological methods using
antibodies reacting with HLA gene products on the cell surface. These methods
rely on obtaining monospecific alloantisera from multiparous females.7 In
addition for class 11 typing suitable B lymphocyte preparations are required.
It is now possible to apply techniques of molecular biology to the problems of
HLA typing. Restriction endonucleases that recognise specific nucleotide
sequences are used to digest DNA. The resulting DNA fragments are then
separated according to size by electrophoresis in agarose gels and transferred to
nylonmembranes. Radiolabelled complementary DNAprobesareusedtoidentify
genes for classI and classII regions. Each probe hybridises withseveral fragments
of DNA, some of which are constant in the general population whereas others
called allogenotypes are present in some persons but absent in others. We
describe the use of a single enzyme/single blot/multiple reprobe system of
HLA-DRand -DQ (developed inthis laboratory inconjunction with DrJBidwell,
United Kingdom Transplant Service, Bristol) to assign by analysis of allogeno-
types the HLA-DR and DQ specificity at the DNA level. We have applied this
technique to typing renal patients in order to assess any differences obtained by
this technique when compared to conventional serological methods.
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MATERIALS AND METHODS
The renal population consisted of 160 patients either transplanted consecutively
since May 1986 or awaiting a transplant. DNA was prepared from peripheral
blood leucocytes which were isolated from EDTA blood by two erythrocyte lysis
steps using 2-3 volumes of red cell lysis buffer RCLB (10mM Tris-HCI
pH7-6/5mM MgCI2/10mM NaCI). The leucocytes were resuspended in 2ml
RCLB followed by the addition of 13ml white cell lysis buffer (10mM Tris-HCI
pH7-6, 10mM EDTA pH8-0, 50mM NaCI, 0-2% sodium dodecyl sulphate,
200pg/ml proteinase K), mixed gently and incubated overnight in a shaking
water bath at420C. Proteins were removed bytwo extractions with 15ml phenol/
chloroform/isoamylalcohol (25:24:1) followed by two 15ml extractions with
chloroform/isoamylalcohol (24:1). DNA wasprecipitated from theaqueous layer
by the addition of 300p1 3M NaCI and 15ml isopropanol. The DNA was
harvested using a sealed glass pasteur pipette, washed three times in 4ml 70%
ethanol, dried and resuspended in TE (1OmM Tris HCI pH7-6, lmM EDTA
pH8-0). The DNA was assayed spectrophotometrically and stored at a final
concentration of 1 -2pg/pi at 4°C.
Samples of genomic DNA (8pg) were digested to completion with the restriction
endonuclease Taq 1 (Bethesda Research Laboratories, 5 units/pg DNA) and
resolved using agarose gel electrophoresis for 18hr at 40V in an agarose gel
(25 x 20 x 0-6cm, 0-7% w/v agarose (Bethesda Research Laboratories) in
TAE electrophoresis buffer (40mM Tris -acetate, 1 mM EDTA containing
0.5pg/ml ethidium bromide)). The DNA was denatured, transferred to a nylon
membrane (Amersham Hybond -N)and hybridised.8 Membranes were hybridised
sequentially with the following radiolabelled exon -specific cDNA probes;
HLA-DRJ3 pRTV1,8 HLA-DQ13 p11-B3-I9 and HLA-DQa pDCH1.10 After
autoradiography the membranes were dehybridised by washing, with gentle
agitation, at 420C in 500ml 0-4M NaOH for 30min followed by 500ml 0-2M
Tris-HCI pH7-6 0-5% SDS for 30min prior to rehybridisation.
RESULTS
The figure shows the allogenotypes revealed using the DR13 cDNA probe pRTV1.
The allogenotypes DRJ3l, 32,j33,j34,j37,j38,39,j311,1312,,6313,j314 are associated
with the corresponding HLA -DR serological specificities. Allogenotypes are also
observed which are subtypes of individual DR specificities not previously differ-
entiated by serological methods i.e. DR.331, 32 and DRR13aI, 13a2, 13a3, 13a4.
The figure also shows the results of rehybridising the membrane with the
DQ13 and DQ a cDNA probes respectively. Using the DQ13 probe, six DQj3
allogenotypes are identified (131a,J31b,132a,132b,J33a,133b). These allogenotypes
correlate with known serological types of DQ i.e. J31a and J31b with DQwl
serotypes; J32a and 132b with DQw2 serotypes; 133a and 133b with DQw3
serotypes.
Using the DQ a probe, five DQ a allogenotypes are identified ( a 1a, a 1b, at 1c,
a 2 and a 3). These describe another allelic series which also correlates with
serological types of DQ, though to a lesser degree than the absolute correlation
seen with DQ13 allogenotypes. Thus DQ a la, alb and alc correlate with DQwl
serotypes though c 1b is also associated with DQw3, and a2 and a3 allogeno-
types are both associated with DQw2 and DQw3 serotypes.
( The Ulster Medical Society, 1988.
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Figure. Allogenotypes found using Taq I and the DRJ3, DQJ3 and DQa probes.
When the results obtained by allogenotyping were compared to those obtained
by serology, there was a difference in 25 (16%) of the patients. In 5 patients an
incorrect antigen had been assigned by serological typing. On two occasions
DRwl3 had been assigned instead ofDR3 and on a furthertwo occasions instead
of DRwl2. On one occasion DRwl2 was assigned instead of DRw13. In 20
patients an antigen detected by allogenotyping was not detected by serolgy. The
antigen HLA-DRBr was not detected in 11 patients, HLA-DRwB was not
detected in 2 patients, HLA-DRw14 was not detected in 2 patients and the
following antigens were not detected on one occasion in separate patients;
HLA-DR1, -DR3, -DR4, -DR9, -DRw13.
DISCUSSION
The methods described in this report permit the assignment of HLA-DR and
-DQ specificities by the sequential use of short DRJ3, DQJ3 and DQa DNA
probes. The DRJ3, DQI3 and DQ a allogenotypes in heterozygotes are interpreted
by the summation of patterns demonstrated by homozygous control cells.
A major application of DNA typing is in the interpretation of HLA-DR and DQ
specificities where serological assignment is not possible or where the results are
equivocal. Serological assignment isinfluenced by poorquality orlow numbersof
circulating B cells and by the lack of reliable monospecific alloantisera for certain
specificities.
Our results have shown that the majority (20/25) of differences between the
serological and allogenotyping method are duetothe detection byallogenotyping
i The Ulster Medical Society, 1988.
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of antigens which are not detected by the serological method. The remaining five
discrepancies arose due to the difficulties involved in the serological typing of
DRwl3, an antigen for which it is difficult to obtain monospecific sera. Thus all
the differences that have occurred are due to the unavailability of suitable sera.
On all occasions when differences between the allogenotype and the serological
type are found, it is possible, using the allogenotype result, to assess the quality
of the HLA sera.
We can now assign DQ specificities using allogenotyping, which we could not do
by serological means because all the DQ sera available to this laboratory are
contaminated with DR antibodies. For example, all available DQwl sera always
contain antibodies against one or more ofthe DR antigens associated with DQwl
(DR1, DR2 and DRw6).
There are two main disadvantages at present to the allogenotyping: cost and
length of time to perform the technique. The difficulties in cost are due to the
initial setting-up of the technique. Once the techniques are established then the
cost of DNA typing is very similar to the cost ofserological typing. The technique
is not readily applicable to cadaver donor typing since it is incompatible with the
clinical urgency set by organ ischaemia time. In the future it should be possible to
shorten the time taken by using allele specific probes.
The DNA methods can also be applied to disease studies. At present we are
investigating multiple sclerosis patients with a variety of endonucleases to
determine any differences in the size of the resulting DNA fragments between
patients and controls. Previous disease studies, using Taq 1 restriction enzyme
and DRJ3 and DQJ3 probes, have identified a restriction fragment pattern observed
in 11 of 12 DR3/4 patients with insulin dependent diabetes mellitus but absent in
all 12 DR -matched controls.1 1
A further possible application of DNA typing is the replacement of the mixed
lymphocyte culture for measuring differences between donor and recipient in
bone marrow transplantation. Using a variety of endonucleases and probes, it
should be possible to determine if there are any differences between recipient
and donor. This would be extremely useful in those instances where donor and
recipient sibling are separated by geography or where the use of a non -related
HLA identical donor is contemplated.
Already DNA typing has proved most useful in this laboratory. As the technique
is developed, it should be possible to identify splits of DR antigens and more
generally to provide further insight into the genetic complexity of the human
major histocompatibility complex.
We are grateful to the Multiple Scleroris Society (Northern Ireland Branch) for their generosity in
providing us with equipment and staff to enable us to perform these techniques, and to Miss Denise
Fulton for typing the manuscript.
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